A global Pharma company wanted to understand the current treatment and level of unmet need across 10 oncology indications in both the US and 5EU to help guide their strategic direction for their portfolio.
GlobalData supported the client to understand the opportunity for their assets including the current Standard of Care (SoC), current level of unmet need, pipeline assessment, identifying promising products in the pipeline – how they are likely to address the current unmet needs and impact treatment practices. This information fed into the company’s launch strategy planning.
Our Solution
- GlobalData leveraged its proprietary platforms and conducted in-depth KOL interviews to give the client a comprehensive overview of the disease landscape specific to each international market of interest.
- GlobalData also leveraged its epidemiological data from syndicated team. These were complemented with additional secondary research and triangulated with an in-depth literature search, in order to validate, refine and tailor the data that would feed into the market landscape outputs.
- The core deliverables contained a presentation consolidating the competitive landscape, guidelines, pipeline assessment and primary market research across each of the markets and indications.
Outcome
Through creation of 10 presentations, one for each oncology indication of interest, GlobalData supported the client’s launch decision for the indications in the Western markets (US and 5EU). The project involved a strong component of collaboration between GlobalData and the client’s leadership teams.
Our consultants work closely with you to understand requirements and develop a tailored approach and deliverables.
